

DRUG NAME: Mitoxantrone**SYNONYM(S):** Dihydroxyanthracenedione,¹ DHAD^{1,2}**COMMON TRADE NAME(S):** Mitoxantrone injection, NOVANTRONE® (USA)**CLASSIFICATION:** intercalating agent-antitumour antibiotic, cytotoxic³*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Mitoxantrone is a synthetic anthracenedione that is structurally similar to doxorubicin and daunorubicin.^{2,4} It was synthesized with the goal to reduce anthracycline side effects, particularly cardiotoxicity.⁵ Mitoxantrone inhibits DNA repair by inhibiting topoisomerase II^{4,6} which results in fragmentation of DNA.⁷ Mitoxantrone is an immunosuppressive agent^{4,6} that may also generate free radicals, inhibit protein kinase C, cause electrostatic DNA cross-links, and induce apoptosis.² Although maximally cytotoxic in the S-phase, mitoxantrone is not cell cycle phase-specific.^{2,8} Cross-resistance with anthracyclines has been demonstrated.²

PHARMACOKINETICS:

Oral Absorption	poor ⁶	
Distribution	extensive tissue distribution; 3X greater AUC in patients with severe hepatic dysfunction	
	cross blood brain barrier?	not to an appreciable extent
	volume of distribution ⁶	14 L/kg; distributes into pleural fluid, kidney, thyroid, liver, heart, and red blood cells
	plasma protein binding ⁶	>95%; 76% to albumin
Metabolism	hepatic, pathways undetermined	
	active metabolite(s)	no information found
	inactive metabolite(s) ⁹	yes
Excretion	urine ^{2,6}	6-11%; 65% unchanged
	feces ⁶	25%; 65% unchanged
	terminal half life	23-215 h; prolonged by hepatic impairment
	clearance ¹⁰	10.9-37.4 L/hr/m ²
Elderly	decreased clearance	

Adapted from standard reference⁴ unless specified otherwise.**USES:****Primary uses:**

*Leukemia, including acute non-lymphocytic
Prostate cancer¹¹

Other uses:

*Breast cancer
*Hepatoma
*Lymphoma
Pediatric sarcoma⁶

*Health Canada approved indication

SPECIAL PRECAUTIONS:**Contraindications:**

- history of hypersensitivity reaction to anthracyclines or mitoxantrone⁴
- severe hepatic impairment⁴; safety in patients with hepatic impairment has not been established⁴; reduced dosage has been used⁴

Caution: when used in combination regimens, the initial dose should be reduced by 2-4 mg/m² below the recommended dose for single-agent usage⁴

Cardiac toxicity is a risk of mitoxantrone therapy that may be manifested by acute or delayed events⁴; see paragraph following the **Side Effects** table for more information. Risk factors for developing mitoxantrone-induced cardiotoxicity include⁴:

- high cumulative dose (>100 mg/m²); if exceeded, monitor for evidence of cardiac toxicity prior to each subsequent dose
- previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease [left ventricular ejection fraction (LVEF) <50% or a clinically-significant reduction in LVEF]
- concomitant use of other cardiotoxic drugs

Carcinogenicity: Studies not performed to date.⁴ Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) have been reported when used alone but more so when used with other antineoplastic agents and/or radiation.⁴

Mutagenicity: Mutagenic in microbial mutagenicity tests.⁴ Mitoxantrone is clastogenic in mammalian *in vivo* chromosome tests; at doses approximating clinical use levels, the clastogenic effect is reversible.⁴

Fertility: Amenorrhea and a typically reversible reduction in spermatogenesis have been reported.^{4,9,12} At the highest tolerated doses allowing evaluation of reproduction in rats, mitoxantrone had no effect on fertility.⁴

Pregnancy: FDA Pregnancy Category D.⁶ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Breastfeeding is not recommended due to secretion into breast milk.⁴

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.¹³

ORGAN SITE	SIDE EFFECT
Mitoxantrone is typically well tolerated at standard doses. ⁴	
Clinically important side effects are in bold, italics	
allergy/immunology	allergic reactions; including anaphylaxis (<1%) ⁶
blood/bone marrow/ febrile neutropenia	<i>anemia</i> (5-75%) ⁶
	<i>leukopenia</i> (9-100%) ⁶ ; nadir typically occurs on day 10 with recovery by day 21
	<i>myelosuppression</i> ; dose-limiting; severe myelosuppression is rare
	thrombocytopenia (33-39%) ⁶
cardiovascular (arrhythmia)	arrhythmia (3-18%) ⁶ ; including sinus bradycardia
	ECG changes ⁶ (11%) ⁶

ORGAN SITE	SIDE EFFECT Mitoxantrone is typically well tolerated at standard doses. ⁴
Clinically important side effects are in bold, italics	
cardiovascular (general)	cardiomyopathy
	CHF (2-5%) ^{4,6} ; may occur during and months to years after treatment; deaths have occurred
	decreased left ventricular ejection fraction ($\leq 13\%$) ^{4,6} ; may occur during and months to years after treatment
	hypertension ⁶ (4%) ⁶
	hypotension
	ischemia ⁶ (5%) ⁶
	myocardial infarction
constitutional symptoms	diaphoresis ⁶ (9%) ⁶
	fatigue ($\leq 39\%$) ⁶
	fever (6-78%) ⁶
	weight changes (13-17%) ⁶
dermatology/skin	extravasation hazard: irritant ¹⁴ ; rare cases of tissue necrosis have been reported; reversible blue discoloration of the skin has occurred with extravasation
	alopecia* (15-61%, severe 1%) ^{4,6} ; typically mild; case reports of selective alopecia of white but not dark hair ⁹
	bruising ⁶ (6-11%) ⁶
	nail pigmentation
	onycholysis (11%) ⁶
gastrointestinal	emetogenic potential: low to low- moderate ¹⁵
	anorexia (22-25%) ⁶
	constipation (10-16%) ⁶
	diarrhea* (4-47%) ^{6,9}
	dyspepsia ⁶ (5-14%) ⁶
	nausea and vomiting* (10-35%, severe 4%) ^{4,9} typically mild and transient
	stomatitis/mucositis* (4-54%, severe <1%) ^{4,6,9} ; typically occurs within 1 week of treatment ⁹
	ulcers ⁶ (10%) ⁶
hemorrhage	gastrointestinal bleed (2-16%) ⁶
	hemorrhage* (6%) ⁶
hepatobiliary/pancreas	hepatic toxicity* (<1%) ⁹ ; severe impairment reported in leukemic patients
infection	infection*; including urinary tract (7-32%), ⁶ upper respiratory tract (7-53%), ⁶ pneumonia (9%) ⁶
lymphatics	edema (10-31%) ⁶
metabolic/laboratory	hyperglycemia ⁶ (10-31%) ⁶ ; likely related to concurrent steroid administration ¹³
	hyperuricemia
	hypocalcemia (10%) ⁶

ORGAN SITE	SIDE EFFECT Mitoxantrone is typically well tolerated at standard doses. ⁴
Clinically important side effects are in bold, italics	
	hypokalemia (7-10%) ⁶
	hyponatremia ⁶ (9%) ⁶
	increased blood urea nitrogen (22%)
	increased liver enzymes (\leq 37%) ^{6,9}
	increased serum creatinine (13%) ⁶
	proteinuria ⁶ (6%) ⁶
musculoskeletal	weakness (24%) ⁶
neurology	anxiety (5%) ⁶
	confusion
	depression ⁶ (5%) ⁶
	drowsiness
	paraesthesia
	seizures ⁶ (2-4%) ⁶
ocular/visual	blue discoloration of the sclera (<1%); reversible
	blurred vision ⁶ (3%) ⁶
	conjunctivitis ⁶ (5%) ⁶
pain	headache (6-13%) ⁶
	pain ⁶ (8-41%) ⁶ ; including abdominal pain (9-15%), ⁶ back pain ⁶ (8%), ⁶ myalgia ⁶ (5%), ⁶ arthralgia ⁶ (5%) ⁶
pulmonary	cough ⁶ (5-13%) ⁶
	dyspnea (6-18%) ⁶
	rhinitis/sinusitis ⁶ (5-6%) ⁶
renal/genitourinary	blue-green colouration of urine (6-11%) ⁶ ; typically occurs for 24h after treatment
	hematuria ⁶ (11%) ⁶
	renal toxicity (8%) ⁶
secondary malignancy	AML and MDS (~1-2%) ^{4,6}
sexual/reproductive function	amenorrhea (28-53%), ⁶ menstrual disorder ⁶ (26-61%) ⁶
	impotence ⁶ (7%) ⁶
	reduction in spermatogenesis; typically reversible ^{4,9,12}
syndromes	tumour lysis syndrome (<1%)

Adapted from standard reference⁴ unless specified otherwise.

***In leukemic patients**, due to higher doses used, the side effects profile may differ; the following toxicities have been reported^{8,8}:

- diarrhea, 9-13%
- increased incidence of bleeding and infection; sepsis, 31-34%
- moderate nausea or vomiting, 8%
- moderate or severe alopecia, 11 %
- moderate or severe stomatitis/mucositis, 9-29%
- moderate or severe jaundice or hepatitis, 8%

Cardiotoxicity may manifest as EKG changes, an asymptomatic decrease in LVEF, cardiomyopathy, and symptomatic congestive heart failure (CHF).^{4,6} Evaluation of LVEF is recommended⁴:

- prior to initiating therapy
- if signs and symptoms of CHF develop
- in patients with risk factors; see paragraph in the **Special Precautions** section for more information
- prior to all doses received after a cumulative dose of 100 mg/m² is reached

Cardiotoxicity is cumulative across all anthracyclines and anthracenediones and is thought to be due to in part to free radical damage.^{2,16} Irreversible CHF may occur during therapy or months to years afterwards; deaths have occurred. At the cumulative dose of 140 mg/m², the incidence of symptomatic CHF and moderate or severe decline in LVEF are 2.6 and 13 percent respectively.⁴ Like the anthracyclines, mitoxantrone-induced heart failure responds to standard medical therapy.⁴

Hyperuricemia may result from cell lysis by cytotoxic chemotherapy and may lead to electrolyte disturbances or acute renal failure.¹⁷ It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients¹⁸:

- aggressive hydration: 3 L/m²/24 hr with target urine output > 100 mL/hr
- if possible, discontinuation of drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitoring of electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- electrolyte replacement as required
- allopurinol 600 mg po initially, then 300 mg po q6h x 6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH > 7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.¹⁹ It may be used for treatment or prophylaxis of hyperuricemia, 0.2 mg/kg IV daily for up to 7 days; however, its place in therapy has not yet been established.

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
quinolones (e.g., ciprofloxacin) ²⁰	delayed, moderate, possible; the antimicrobial effect of quinolones may be decreased	quinolone absorption decreased due to alteration of the intestinal mucosa	monitor for response to quinolone therapy, adjust quinolone dose as necessary

SUPPLY AND STORAGE:

Injection: Hospira Healthcare Corporation supplies mitoxantrone as a 2 mg/mL dark blue solution in 10 and 12.5 mL single-use vials. Store at room temperature; do not freeze. Protect from light.⁴

Novopharm Limited supplies mitoxantrone as a 2 mg/mL dark blue solution in 10 mL single-use vial. Store at room temperature; do not freeze. Protect from light.⁸

Pharmaceutical Partners of Canada supplies mitoxantrone as a 2 mg/mL dark blue solution in 10 mL single-use vial. Store at room temperature; do not freeze.⁷ Product is not light- sensitive.²¹

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Additional information: should be diluted to at least 50 mL prior to use^{4,7,8}

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

BCCA administration guideline noted in **bold, italics**

Subcutaneous ⁴	not recommended
Intramuscular ⁴	not recommended
Direct intravenous	not recommended; has been used ^{6,22-24}
Intermittent infusion ^{2,4}	slowly (over 3-5 minutes; typically given over 15-30 minutes) into tubing of running IV
Continuous infusion ^{1,6}	has been used
Intraperitoneal ^{4,9}	has been used
Intrapleural ²⁵	investigational
Intrathecal ⁴	not recommended; neuropathy and neurotoxicity including paralysis, seizures, and bowel and bladder dysfunction have occurred
Intra-arterial ⁴	not recommended; local/regional neuropathy which may be irreversible has been reported
Intravesical ^{26,27}	investigational

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BCCA usual dose noted in **bold, italics**

<i>Intravenous:</i>	Cycle Length: 3-4 weeks ^{2,4,6,11} :	12-14 mg/m² IV for one dose on day 1 (total dose per cycle 12-14 mg/m ²)
	induction ⁴ :	12 mg/m ² IV once daily for 5 consecutive days starting on day 1 (total dose 60 mg/m ²)

BCCA usual dose noted in ***bold, italics***

	Cycle Length: induction and re- induction ^{2,4} :	10-12 mg/m ² IV once daily for 2-3 consecutive days starting on day 1 (total dose per cycle 20-36 mg/m ²)
	consolidation: ^{2,4} :	12 mg/m ² IV once daily for 2 consecutive days starting on day 1 (total dose per cycle 24 mg/m ²)
<i>Suggested maximum cumulative dose</i> ⁴ :		100 mg/m ² ; see cardiotoxicity paragraph following the Side Effects table
<i>Concurrent radiation</i> :		has been used ²⁸⁻³¹
<i>Dosage in myelosuppression</i> :		modify according to protocol by which patient is being treated or the product monograph; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"
<i>Dosage in renal failure</i> :		safety and effectiveness have not been established ⁴ ; limited renal excretion, adjustment likely not required ²
<i>Dosage in hepatic failure</i> :		consider dosage adjustment ⁶ ; no dosing details found, contraindicated in severe hepatic impairment ⁴
<i>Dosage in dialysis</i> :		extensive tissue binding; unlikely cleared by dialysis; supplemental dose not required ^{6,32}

Children:

<i>Intravenous</i> :	Cycle Length:	safety and effectiveness have not been established ⁴ ; has been used ^{1,4,33}
	n/a ^{1,33} :	8-12 mg/m ² IV once daily for 3-5 consecutive days starting on day 1 (total dose 24-60 mg/m ²)
	n/a ¹ :	0.4 mg/kg/day IV once daily for 3-5 consecutive days starting on day 1 (total dose 1.2-2.0 mg/kg)
	n/a ¹ :	12 mg/m ² IV once daily for 2-3 consecutive days starting on day 1 (total dose 24-36 mg/m ²)
	3-4 weeks ¹ :	18-20 mg/m ² IV for one dose on day 1 (total dose per cycle 18-20 mg/m ²)

REFERENCES:

1. Rose BD editor. Mitoxantrone: Pediatric drug information. UpToDate 15.3 ed. Waltham, Massachusetts: UpToDate®; 2008.
2. McEvoy GK, editor. AHFS 2007 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1143-1145.
3. National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; September 2004. p. 31-40.
4. Hospira Healthcare Corporation. Mitoxantrone Injection, USP Product Monograph. Saint-Laurent, Quebec; 13 June 2007.

5. Floyd J, Morgan JP, Perry MC. Cardiotoxicity of anthracycline-like chemotherapy agents. UpToDate 15.3 ed. Waltham, Massachusetts: UpToDate®; 2007.
6. Rose BD editor. Mitoxantrone. UpToDate 15.3 ed. Waltham, Massachusetts: UpToDate®; 2008.
7. Pharmaceutical Partners of Canada. Mitoxantrone Injection Package Insert. Richmond Hill, Ontario; February 2007.
8. Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19 May 2005.
9. DRUGDEX® Evaluations (database on the Internet). Mitoxantrone. Thomson MICROMEDEX®, 2008. Available at: www.micromedex.com. Accessed 25 January 2008.
10. Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. *Clin Pharmacokinet* 1990;18(5):365-380.
11. BC Cancer Agency Genitourinary Tumour Group. (GUPMX) BCCA Protocol Summary for Palliative Therapy for Hormone Refractory Prostate Cancer Using Mitoxantrone and Prednisone. Vancouver, British Columbia: BC Cancer Agency; 1 February 2007.
12. Lemez P, Urbanek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhoea in middle-aged patients. *Neoplasma* 2005;52(5):398-401.
13. Lyly Le MD. Personal communication. BC Cancer Agency Genitourinary Tumour Group; 12 March 2008.
14. BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 September 2006.
15. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 November 2005.
16. Mott MG. Anthracycline cardiotoxicity and its prevention. 824:221-8. *Annals of the New York Academy of Sciences*. 1997;824:221-228.
17. DeVita VT, Hellman S, Rosenberg SA. *Cancer Principles & Practice of Oncology*. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001. p. 2640.
18. Leukemia/Bone Marrow Transplant Program of British Columbia. *Leukemia/BMT Manual*. 4th ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2003. p. 27.
19. Abraxis Pharmaceutical Products. Dacarbazine product information package. Schaumburh, IL; December 2006.
20. Drug Interaction Facts (database on the Internet). Procarbazine. Facts and Comparisons 4.0, 2008. Available at: <http://online.factsandcomparisons.com>. Accessed 7 March 2008.
21. Josephine Holmes. Personal communication. Manager Regulatory Affairs, Pharmaceutical Partners of Canada Inc.; 28 Jan 2008.
22. Hainsworth JD, Jones SE, Mennel RG, et al. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: A phase II trial. *Journal of Clinical Oncology* 1996;14(5):1611-1616.
23. Carmo-Pereira J, Costa FO, Henriques E. Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study. *European Journal of Cancer Part A: General Topics* 1993;29(13):1814-1816.
24. Kakolyris S, Samonis G, Koukourakis M, et al. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials* 1999;22(3):273-277.
25. Windsor PG, Como JA, Windsor KS. Sclerotherapy for malignant pleural effusions: Alternatives to tetracycline. *South Med J*. 1994;87(7):709-714.
26. Flamm J, Donner G, Oberleitner S, et al. Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study. *European Journal of Cancer Part A: General Topics* 1995;31(2):143-146.
27. Porter P, Cornaby AJ, Al-Hilali M, et al. Primary lymphoma of the bladder treated successfully with mitoxantrone gel. *Postgrad Med J*. 1999;75(888):609-610.
28. Toledano A, Azria D, Garaud P, et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: Final results of the ARCOSEIN trial. *Journal of Clinical Oncology* 2007;25(4):405-410.
29. Rouesse J, De La Lande B, Bertheault-Cvitkovic F, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results. *International Journal of Radiation Oncology Biology Physics* 2006;64(4):1072-1080.
30. Macquart-Moulin G, Viens P, Genre D, et al. Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: Side effects, quality of life, and daily organization. *Cancer* 1999;85(10):2190-2199.
31. Gedlicka C, Schull B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. *Anticancer Drugs* 2002;13(5):491-495.
32. Aronoff GR, Bennett WM, Berns JS, Brier ME, et al. *Drug Prescribing in Renal Failure: Dosing guidelines for adults and children*. 5th ed. Philadelphia, Pennsylvania: American College of Physicians; 2007. p. 101.
33. Pizzo P, Poplack D. *Principles and Practice of Pediatric Oncology*. 5th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2006. p. 303.